SWOG clinical trial number
SWOG-9509

A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine and Cisplatin in Untreated Advanced Non-Small Cell Lung Cancer

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine and Cisplatin in Untreated Advanced Non-Small Cell Lung Cancer
Activated
04/01/1996
Closed
01/01/1998

Research committees

Lung Cancer

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

A Clinical Prognostic Model for Survival of Elderly Patients with Non-Small Cell Lung Cancer

AK Ganti;X Wang;TE Stinchcombe;YA Wang;K Kelly;R Paulus;JD Bradley;S Ramalingam;H Cohen;E Vokes;H Pang IASLC World Conference on Lung Cancer (October 15 - 18 2017, Yokohama, Japan), accepted, oral

2014

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2013

Chemotherapy outcomes by histological subtypes of non-small cell lung cancer: analysis of the SWOG database for antimicrotubule-platinum therapy

K Kelly;K Chansky;P Mack;P Lara;FR Hirsch;WA Franklin;A Wozniak;MJ Edelman;SK Williamson;DR Gandara Clinical Lung Cancer 14(6):627-635;

PMid: PMID23910067 | PMC number: PMC4122504

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

2009

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

2008

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials [PMID18202421]

PN Lara Jr;MW Redman;K Kelly;MJ Edelman;SK Williamson;JJ Crowley;DR Gandara Journal of Clinical Oncology 26(3):463-467

Interim futility analysis with intermediate endpoints

B Goldman;M LeBlanc;J Crowley Clinical Trials 5(1):14-22

PMid: PMID18283075

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer

H Wakelee;K Kernstine;E Vokes;J Schiller;P Baas;N Saijo;A Adjei;G Gross;L Gaspar;D Gandara;H Choy;JB Putnam Clinical Lung Cancer 9(6):345-351

PMid: PMID19073517 | PMC number: (Reviews are not within the scope of the Public Access)

2007

Toxicity and survival by sex in patients with advanced non small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials.

KS Albain;JM Unger;CC Gotay;AM Davies;M Edelman;RS Herbst;K Kelly;SK Williamson;AJ Wozniak;DR Gandara Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7549

Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions

PA Ganz;CC Gotay Journal of Clinical Oncology 25(32):5063-9

PMid: PMID17991922

2006

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: implications for clincial trial design

PN Lara;MW Redman;K Kelly;MJ Edelman;SK Williamson;JJ Crowley;DR Gandara Proc of the ASCO, Journal of Clinical Oncology 24(18S):#7006

2003

Time from treatment to subsequent diagnosis of brain metastases in Stage III non-small cell lung cancer (NSCLC): a retrospective review by the Southwest Oncology Group (SWOG)

LE Gaspar;K Chansky;KS Albain;E Vallieres;V Rusch;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 22:636(#2558)

Molecular abnormalities of DNA damage and anti-microtubule response pathways in non-small cell lung carcinomas (NSCLC) from patients on the Southwest Oncology Group (SWOG) 9509 trial

PC Mack;IV Galvin;T Kimura;WA Franklin;KD Danenberg;K Chansky;WS Holland;JJ Crowley;DR Gandara;PH Gumerlock Proc of the American Society of Clinical Oncology 22:639(#2569)

2002

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small cell lung cancer

SD Ramsey;CM Moinpour;LC Lovato;JJ Crowley;P Grevstad;CA Presant;SE Rivkin;K Kelly;DR Gandara Journal of the National Cancer Institute 94(4):291-297

Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial

CM Moinpour;B Lyons;PK Grevstad;LC Lovato;J Crowley;K Czaplicki;ZM Buckner;PA Ganz;K Kelly;DR Gandara Quality of Life Research 11:115-126

Tests for lifetime utility or cost via calibrating survival time

Y Huang;L Lovato Statistica Sinica 12:707-723

2001

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial

K Kelly;J Crowley;PA Bunn;CA Presant;PK Grevstad;CM Moinpour;SD Ramsey;AJ Wozniak;GR Weiss;DR Moore;VK Israel;RB Livingston;DR Gandara Journal of Clinical Oncology 19(13):3210-3218

Should older patients (PTS) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? an analysis of Southwest Oncology trials 9509 and 9308.

K Kelly;S Giarritta;S Hayes;W Akerley;P Hesketh;A Wozniak;K Albain;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 20:329a(#1313)

2000

An economic analsis of Southwest Oncology Group trial S9509: Cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer

SD Ramsey;CM Moinpour;LC Lovato;PK Grevstad;K Kelly;C Presant Proc of the American Society of Clinical Oncology 19:489a(#1913)

An economic analysis alongside a prospective randomized multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non small cell lung cancer.

SD Ramsey;CM Moinpour;LC Lovato;PK Grevstad;C Presant;DR Gandara;K Kelly Lung Cancer 29(Suppl.2):4(#5)

Current status of therapy for advanced non-small cell lung cancer: a perspective from the Southwest Oncology Group (SWOG)

DR Gandara;K Kelly;P Gumerlock;J Crowley Lung Cancer 29(Suppl.2):186

1999

A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial.

K Kelly;J Crowley;PA Bunn;RB Livingston;DR Gandara Proc of the American Society of Clinical Oncology 18:461a(#1777)